Trial ID or NCT#

NCT01980732

Status

NOT RECRUITING

Purpose

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Official Title

68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Frederick T. Chin, Ph.D.
Pamela L. Kunz
Medical oncologist
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Andrei Iagaru
Radiologist
Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center
Jeffrey Norton, MD
Surgical oncologist
The Robert L. and Mary Ellenburg Professor in Surgery

Contact us to find out if this trial is right for you.

CONTACT

Krithika Rupnarayan
(650) 736-0959